← All Mangoceuticals, INC filings

Mangoceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MGRX
Mangoceuticals, INC
10-K: Mangoceuticals Faces Mounting Losses, Going Concern Warning Amid Strategic Shifts
Mangoceuticals, Inc. reported a significant increase in net loss for 2025, alongside a going concern warning, as it navigates strategic shifts into digital assets and new product development.
NASDAQ
MGRX
Mangoceuticals, INC
10-K: Mangoceuticals, Inc. Reports Annual Results for Fiscal Year 2024, Navigating Challenges and Charting Future Growth
Mangoceuticals, Inc.'s 2024 annual report reveals a year of strategic shifts, including a subsidiary reorganization and patent acquisitions, amidst ongoing financial challenges and a net loss of $8.7 million.
NASDAQ
MGRX
Mangoceuticals, INC
10-K: Mangoceuticals, Inc. Files 10-K, Details Financials and Operational Strategy
Mangoceuticals, Inc.'s 10-K filing outlines their business model, financial results, and future plans, including challenges with Nasdaq compliance and reliance on related-party transactions.